Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):e206-e207. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0164

View: 554 Download: 19

Editorial

Screening of patients at high risk of de novo recurrence in HCC: Editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Ping Huang, Shiqiao Luo, Rui Liao

Clin Mol Hepatol. 2025;31(2):662-664. Published online February 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0106

View: 548 Download: 30

Original Article

Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma

Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):563-576. Published online January 13, 2025

DOI: https://doi.org/10.3350/cmh.2024.0899

View: 1116 Download: 81

Correspondence

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Clin Mol Hepatol. 2025;31(1):e70-e73. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761

View: 1081 Download: 62

Editorial

A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”

Johanna K. DiStefano, Glenn S. Gerhard

Clin Mol Hepatol. 2025;31(1):297-300. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0704

View: 979 Download: 30 Crossref: 1

Original Article

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim, on behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

Clin Mol Hepatol. 2024;30(4):824-844. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229

View: 3167 Download: 323 Web of Science: 3 Crossref: 2

3

Methylation of the Tumor Suppressor Gene RUN×3 in Human Gastric Carcinoma

Hyun Joo Song , Ki Nam Shim , Yang Hee Joo , Seong Eun Kim , Sung Ae Jung , Kwon Yoo

Clin Mol Hepatol. 2008;12(2):119-125.

View: 2024 Download: 12

Original Article

GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome

Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, Xin He, Hui Zhang, Ming Tan, Hai-Bo Yu, Zhen-Zhen Zhang, Ji-Hua Ren, Min-Li Yang, Da-Peng Zhang, Zhi-Hong Li, Juan Chen

Received August 21, 2024 Accepted January 28, 2025

DOI: https://doi.org/10.3350/cmh.2024.0694 [Accepted]

View: 1109 Download: 215

Editorial

Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”

Mehrangiz Dezhbord, Kyun-Hwan Kim

Received April 2, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0366 [Accepted]

View: 238 Download: 39

1 |

Viewed By 10225	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7246	MAFLD: How is it different from NAFLD?
Viewed By 5237	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4722	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4676	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 208	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 103	Non-alcoholic fatty liver disease: Definition and subtypes

Search